About
Immunosuppression Therapies
Areas of Focus
Categories
Small Molecule PharmaceuticalNorth & South Carolina
Team (4)
Eric HedgeVice President, Sales
Eric HedgeVice President, SalesEric joined Veloxis in July 2023, bringing more than 25 years of pharmaceutical leadership experience to the Veloxis sales organization.See full bio
Veloxis Pharmaceuticals
executive
Kamal Shah
Veloxis Pharmaceuticals
team_member
Steven G
Veloxis Pharmaceuticals
team_member
Tracy SappVice President, Quality
Tracy SappVice President, QualityTracy joined Veloxis in 2023, bringing more than 15 years of experience in biotechnology and pharmaceutical operations.See full bio
Veloxis Pharmaceuticals
executive
Clinical Trials (43)
View allTotal Trials
43
As Lead Sponsor
17
As Collaborator
26
Total Enrollment
3,169
By Phase
PHASE4: 17EARLY_PHASE1: 3PHASE1: 2PHASE2: 8PHASE2/PHASE3: 4NA: 1PHASE3: 5
By Status
COMPLETED: 23ACTIVE_NOT_RECRUITING: 6RECRUITING: 4TERMINATED: 4WITHDRAWN: 2UNKNOWN: 2NOT_YET_RECRUITING: 1APPROVED_FOR_MARKETING: 1
Clinical Trials Pipeline42 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT06751992Collaborator
Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients
PHASE4Not yet recruiting
92 participants
Started: May 1, 2025 · Completed: Oct 1, 2027
NCT04469842Collaborator
Early Use of Long-acting Tacrolimus in Lung Transplant Recipients
EARLY_PHASE1Recruiting
48 participants
Started: Dec 1, 2023 · Completed: Dec 31, 2026
NCT05238493Lead Sponsor
A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101
PHASE1Completed
60 participants
Started: Apr 26, 2022 · Completed: Jan 3, 2023
NCT05251727Lead Sponsor
Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients
PHASE1Terminated
77 participants
Started: Mar 24, 2022 · Completed: Jun 5, 2024
NCT04773392Collaborator
Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR
PHASE4Recruiting
80 participants
Started: Nov 23, 2021 · Completed: Feb 28, 2025
Locations (1)
Headquarters
Cary, NC, United States
Map
Loading map...